Yavas, G. Et Al. 2017. Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY , vol.22, no.4 , 295-302.

Yavas, G., Celik, E., Yavas, C., Elsurer, C., & Afsar, R., (2017). Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY , vol.22, no.4, 295-302.

Yavas, Guler Et Al. "Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy," REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY , vol.22, no.4, 295-302, 2017

Yavas, Guler Et Al. "Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy." REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY , vol.22, no.4, pp.295-302, 2017

Yavas, G. Et Al. (2017) . "Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy." REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY , vol.22, no.4, pp.295-302.

@article{article, author={Guler Yavas Et Al. }, title={Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy}, journal={REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY}, year=2017, pages={295-302} }